The fifth batch of centralized procurement of these pharmaceutical companies entered

Eight major varieties, many pharmaceutical companies have entered, and the fifth batch of centralized procurement has changed.

1.

The fifth batch of collected varieties reviewed this time are: Esomeprazole Sodium for Injection, Ceftriaxone Sodium for Injection, Paclitaxel Injection, Iodixanol Injection, Cefazolin Sodium for Injection, Fluoride Conazole sodium chloride injection, azithromycin for injection, linezolid glucose injection.

Among them, Esomeprazole Sodium for Injection has been reviewed by 3 pharmaceutical companies this time, namely Suzhou Terui Pharmaceutical Co.

At present, 13 pharmaceutical companies have accumulatively reviewed Esomeprazole Sodium.

Secondly, ceftriaxone sodium for injection has been reviewed by two pharmaceutical companies, namely Sinopharm Zhijun (Shenzhen) Pharmaceutical Co.

Paclitaxel injection has also been reviewed by two pharmaceutical companies this time, namely Wuxi Yew Pharmaceutical Co.

2.

Previously, the state clearly stipulated that if more than 3 manufacturers of the same type of drugs passed the consistency evaluation, the products that failed the consistency evaluation would no longer be selected for centralized drug procurement.

According to data from Minai.

At present, the fifth batch of centralized procurement companies with more than 5 injection products has reached 14 varieties, of which the product with the most over-rated companies is esomeprazole sodium for injection.

According to analysis by industry insiders, the competition in the fifth batch of centralized procurement has eased compared with the first four batches.

In addition to the slight easing of the competitive landscape, as the country's policy of volume procurement matures, low prices are no longer the absolute kingly way.

At the executive meeting of the State Council held on January 15th, the Premier requested that “centralized procurement should reduce the burden on patients while taking into account the reasonable profits of the enterprise” and “work hard to make this reform benefit patients, enterprises, and medical institutions.

Compared with blindly paying attention to price, the state has stricter requirements on quality.
Recently, the Drug Supervision Department of the State Drug Administration organized a special promotion meeting for the supervision of selected drugs in centralized procurement.
The meeting emphasized that local drug regulatory authorities should include selected varieties into the scope of key supervision.
, Establish a supervisory account, strengthen supervision and inspection, especially focusing on products that have won bids at ultra-low prices or have a large price cut.

The meeting proposed that various methods should be used to urge enterprises to continue to produce in compliance, continuously improve their quality management capabilities, crack down on violations of laws and regulations in accordance with the law, and adhere to the bottom line of selected drug quality and safety.

At present, under the vigorous promotion of policies, volume procurement is shifting to normalization, and procurement plans are becoming more mature.
Enterprises should adjust their development strategies according to their own conditions and policy directions.

The competitive landscape of the reviewed varieties on May 31: